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Abstract
Background: Commercial genetic tests for type 2 polysaccharide storage myopathy 
(PSSM2) and myofibrillar myopathy (MFM) have not been validated by peer-review, 
and formal regulation of veterinary genetic testing is lacking.
Objectives: To compare genotype and allele frequencies of commercial test variants 
(P variants) in MYOT (P2; rs1138656462), FLNC (P3a; rs1139799323), FLNC (P3b; 
rs1142918816) and MYOZ3 (P4; rs1142544043) between Warmblood (WB) and 
Arabian (AR) horses diagnosed with PSSM2/MFM by muscle histopathology, and 
phenotyped breed-matched controls. To quantify variant frequency in public reposi-
tories of ancient and modern horse breeds.
Study design: Cross sectional using archived clinical material and publicly available data.
Methods: We studied 54 control-WB, 68 PSSM2/MFM-WB, 30 control-AR, 30 
PSSM2/MFM-AR and 205 public genotypes. Variants were genotyped by pyrose-
quencing archived DNA. Genotype and allele frequency, and number of variant al-
leles or loci were compared within breed between controls, PSSM2/MFM combined 
and MFM or PSSM2 horses considered separately using additive/genotypic and 
dominant models (Fisher's exact tests). Variant frequencies in modern, early domes-
tic and Przewalski horses were determined from a public data repository.
Results: There was no significant association between any P locus and a histopatho-
logical diagnosis of PSSM2/MFM, and no difference between control and myopathic 
horses in total loci with alternative alleles, or total alternate alleles when PSSM2/
MFM was considered combined or separately as PSSM2 or MFM. For all tests, sen-
sitivity was <0.33. Allele frequencies in WB (controls/cases) were: 8%/15% (P2), 
5%/6% (P3a/b) and 9%/13% (P4); in AR, frequencies were: 12%/17% (P2), 2%/2% 
(P3a/b) and 7%/12% (P4). All P variants were present in early domestic (400- to 
5500-year-old) horses and P2 present in the Przewalski.
Conclusions: Because of the lack of significant association between a histopatho-
logical diagnosis of PSSM2 or MFM and the commercial genetic test variants P2, P3 
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1  | INTRODUC TION
Equine polysaccharide storage myopathy (PSSM) is one specific 
form of exertional rhabdomyolysis (ER) that was originally identi-
fied in Quarter Horses and related breeds. Hallmarks used to dis-
cover PSSM were aggregates of amylase-resistant polysaccharide 
in periodic acid-Schiff's (PAS) stains of skeletal muscle and mus-
cle glycogen concentrations greater than 1.5-fold that of normal 
muscle.1 The diagnostic criteria for PSSM subsequently broad-
ened to include amylase-sensitive aggregates of polysaccharide; 
this expanded definition resulted in a wider diversity of breeds 
diagnosed with PSSM.2 In 2008, a dominant, nonsynonymous 
gain-of-function mutation in the glycogen synthase 1 (GYS1) gene 
was identified, refining the classification of PSSM. Horses with 
PSSM attributed to the presence of the GYS1 variant have since 
been classified as having type 1 PSSM (PSSM1).3 The term type 
2 PSSM (PSSM2) therefore was developed as a descriptor for any 
horse that has clinical signs of exercise intolerance and abnormal 
aggregates of polysaccharide in muscle fibres that does not possess 
the GYS1 mutation.4,5 PSSM2 is the most common form of PSSM 
in Warmblood (WB) and Arabian (AR) horses at >80% and 100% 
of PSSM cases, respectively, whereas PSSM1 predominates in the 
continental European-derived draught breeds, Quarter Horses and 
related stock breeds.6,7
Recently, a more in-depth histological analysis of muscle bi-
opsies from AR and WB with PSSM2 revealed that a subset of 
those horses had abnormal aggregates of the cytoskeletal protein 
desmin in a small fraction of mature type 2A muscle fibres.8,9 In 
electron micrographs from these horses, glycogen was found to 
pool between disarrayed myofibrils.8,9 Based on these findings, 
the subset of AR and WB with desmin aggregates that had origi-
nally been diagnosed with PSSM2 was reclassified as having a my-
ofibrillar myopathy (MFM). In WB and AR, the similarity in clinical 
signs in both MFM and PSSM2 supports PSSM2 being an earlier 
manifestation of MFM8-10; however, it has not yet been firmly es-
tablished. MFM is a relatively rare myopathy in humans.11-13 In hu-
mans, mutations in genes that encode proteins in the Z-disc of the 
sarcomere [DES, PLEC 1, CRYAB, FLNC, MYOT, ZASP, BAG3, FHL1 
and DNAJB6] are well-described causes of MFM, with eight other 
genes causing MFM-like disorders.14 In 50% of human MFM cases, 
however, the molecular basis remains unknown.13,14
In horses and other domestic species, genetic tests are com-
mercially available for use in diagnosing and managing disease and 
to inform selection and breeding decisions. For myopathies, such as 
hyperkalaemic periodic paralysis (HYPP), PSSM1, glycogen branch-
ing enzyme deficiency (GBED), malignant hyperthermia (MH) and 
myosin heavy chain myopathies (MYHM), the frequency of each as-
sociated mutation is well described in diseased and healthy popula-
tions, and functional data regarding the effect of each mutation are 
reported in peer-reviewed publications.3,15-19 In human medicine, 
the American College of Medical Genetics and Genomics (ACMGG) 
recommends association or segregation analyses in well-pheno-
typed individuals, as well as modelling and functional studies as 
necessary means to determine that variants identified through 
sequencing are actually causative of disease.20 Although there are 
similar principles for the use of genetic information in commercial 
venues agreed upon by the equine genetic research community, un-
like in human medicine, there is no regulation of veterinary genetic 
testing [consensus statement on the translation and application 
of genomics in equine industries: Horse Genome Project, https://
horse genom ework shop.com/values]. Analyses that determine the 
frequency of a purported causative variant in populations of both 
healthy horses and those diagnosed with the disease using the gold 
standard for diagnosis provide vital information about the accuracy 
of using the mutation as a diagnostic or management tool.
Commercial genetic testing has recently been offered for PSSM2 
and MFM in horses using single-nucleotide polymorphism (SNP) 
variants in genes myotilin (MYOT), filamin C (FLNC) and another 
Z-disc protein not previously reported to cause MFM, myozenin 
(MYOZ3) (Equiseq.com, centerforanimal genetics.com). The variant 
(nonreference) alleles in the commercial test are termed ‘P2’ for that 
in MYOT, ‘P3a’ and ‘P3b’ for those in FLNC and the variant in MYOZ3 
is annotated as ‘P4’. The inference from the test developers is that 
cases of PSSM2 are an early stage of MFM (http://equis eq.com/
learn ing_cente r/healt h/myofi brill ar-myopa thy-mfm). Unlike HYPP, 
PSSM1, GBED, MH and MYHM, there are no peer-reviewed publi-
cations available to validate the scientific basis and diagnostic utility 
of the developers’ PSSM2/MFM genetic tests. Our first objective 
was to compare genotype and allele frequencies of the four variants 
used in commercial genetic testing in WB and AR horses diagnosed 
with MFM or PSSM2 by muscle histopathology compared to those 
of breed-matched, healthy controls. Additionally, we sought to de-
termine allele frequencies at each of the P loci in publicly available 
data including a variety of early equids and modern horse breeds.
2  | MATERIAL S AND METHODS
2.1 | Case selection
The database of the Neuromuscular Diagnostic Laboratory, 
Michigan State University was searched to identify WB and 
and P4 in WB and AR, we cannot recommend the use of these variant genotypes for 
selection and breeding, prepurchase examination or diagnosis of a myopathy.
K E Y W O R D S
horse, muscle disease, glycogen, skeletal muscle, validation
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AR horses with a previous diagnosis of MFM, PSSM2 or both 
based on muscle histopathology. Horses that were diagnosed 
with PSSM2 or MFM or both were then classified as PSSM2/
MFM. All horses identified with MFM were selected for inclu-
sion. Horses with a diagnosis of PSSM2 and no evidence of MFM 
were selected for inclusion if they had DNA already isolated. A 
diagnosis of MFM was based on the presence of desmin-posi-
tive cytoplasmic aggregates in four or more mature myofibres 
(~<1% of fibres/biopsy). Regenerative fibres with dark desmin 
staining rather than aggregates of desmin were excluded from 
diagnostic criteria for MFM. Regenerative fibres were identi-
fied by large internalised myonuclei and basophilic cytoplasm in 
haematoxylin and eosin stains. This is a less stringent criterion 
than that of six or more fibres with desmin aggregates used in 
a previous MFM study8 and was adopted to include all poten-
tial cases of MFM. Desmin staining had been previously per-
formed on all PSSM2/MFM-AR cases and was performed on any 
PSSM2- or control-WB that had not previously been analysed 
in this manner. PSSM2 was diagnosed based on the presence of 
PAS-positive cytoplasmic inclusions in muscle fibres and in WB, 
a negative result for the GYS1 mutation. GYS1 testing had previ-
ously been performed and was negative for 12 PSSM2/MFM-AR 
and not pursued further because the GYS1 mutation is not re-
ported in this breed.21
2.2 | Control selection
The Neuromuscular Diagnostic Laboratory, Michigan State 
University database was screened to identify control 
horses ≥2 years of age from previous research studies that 
were negative for the GYS1 mutation and had normal gluteal or 
semimembranosus muscle histopathology on frozen sections 
stained with a minimum of haematoxylin and eosin, desmin, 
PAS and amylase-PAS stains. Samples that were previously ob-
tained from healthy AR horses housed on several farms across 
the United States were used as controls (n = 30). The repository 
contained muscle biopsies from 10 healthy WB from a variety of 
farms for inclusion as control-WB. To supplement the number of 
control-WB, additional WB were selected from samples submit-
ted by referring veterinarians to the Neuromuscular Diagnostic 
Laboratory, from across the United States with the criteria that 
there were no evident histopathological findings in haematoxy-
lin and eosin, modified Gomori Trichrome, nicotinamide adenine 
dinucleotide tetrazolium reductase, oil red O, PAS, amylase-PAS 
and desmin stains. Preference was given to samples from horses 
with a history consistent with shivers or stringhalt because these 
are not muscle diseases.22,23 There were 11 control-WB that had 
no clinical signs of muscle disease, 16 with a primary complaint 
of shivers/stringhalt, 10 with a hindlimb gait abnormality (ataxia, 
weakness and lameness), seven with atrophy/fasciculations, 
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2.3 | DNA isolation and polymerase chain reaction
DNA was isolated from hair bulbs, buffy coat, whole blood or mus-
cle tissue using Gentra Puregene Kits, and DNA quality/quantity 
evaluated using a Picogreen assay. Thermocycling was carried 
out using recombinant AmpliTaqs Gold polymerase in a PTC-200 
thermocycler, and the PCR products run on a 1.0% agarose gel for 
visualisation.
2.4 | Pyrosequencing
The patent application at https://paten ts.google.com/paten t/
WO201 71657 33A1/en was used to identify the genomic coordi-
nates of the variants as listed in EquCab2.0. The impact of each 
mutation was predicted using Sorting Intolerant From Tolerant 
analysis (SIFT).24 Primers (Table S1) were designed using the 
PyroMark Assay Design Software 2.5.8 and EquCab2.0 reference 
genome, based on the patent application coordinates, with the 
sequence and coordinates confirmed in EquCab3 (Table 1). The 
reverse primer was biotinylated using Biotin-TEG and HPLC puri-
fication (IDT, Coralville, Iowa, USA). The resulting biotin-labelled 
amplicons were annealed with the sequencing primer and the rela-
tive expression of each allele was determined by pyrosequencing 
as described in Kreutz et al.25 Briefly, PCR products were diluted in 
a solution containing 4 ul of streptavidin-coated sepharose beads 
and 40 ul of binding buffer (10 mM Tris-HCL, 2 M NaCl, 1 mM 
EDTA and 0.1% TweenTM 20 pH 7.6). Immobilised biotin-labelled 
amplicons were captured using a vacuum prep tool, washed and 
denatured to remove unbound primers and unbiotinylated strands 
using three solutions (ie 70% ethanol, denaturing solution contain-
ing 0.2 M NaOH and wash buffer containing 10 mM Tris-Acetate 
pH 7.6). Only the template strands remained bound after the 
washing steps. Sepharose beads with bound strands were diluted 
in annealing buffer (20 mM Tris-Acetate and 5 mM MgAc2 pH 7.6) 
containing the sequencing primer and pyrosequenced (PyroMark 
Gold Q96 reagents and PSQ 96MA pyrosequencer, Biotage, 
Charlotte, North Carolina, USA). Relative levels of each allele were 
quantified with the PyroMark AQ 2.5.8 software. All sample plates 
were analysed with positive controls consisting of horses with the 
alternate allele identified from RNA-seq data (GEO Series acces-
sion number GSE10 4388) and a template control containing no 
DNA. Resulting data were visually evaluated to determine geno-
type and allele frequencies. Genotypes were verified across all 
four variants in three horses by Sanger sequencing.
2.5 | Publicly available databases
The frequency of the reference and alternate alleles for the P2, P3a, 
P3b and P4 loci was determined in all horses identified by search-
ing the NCBI Sequence Read Archive (https://www.ncbi.nlm.nih.
gov/sra) using the query: "Equus caballus"[Organism] OR equus 
caballus[All Fields]) AND "biomol dna"[Properties] AND "strategy 
wgs"[Properties] AND "platform illumina"[Properties] AND sra_nuc-
core_alignment [Filter]. For instances where the genome build dif-
fered in reference or query databases, the appropriate coordinates 
were obtained using NCBI Coordinate Remapping Service (https://
www.ncbi.nlm.nih.gov/genom e/tools/ remap/). A minimum coverage 
of five reads was required at each locus to call genotypes, which was 
performed using SRA tools pileup stats. Samples without sufficient 
coverage at a given locus were excluded from allele frequency calcu-
lations. The horses represented 25 breeds as well as ‘early domestic’ 
(400-5500 years old) samples, one ancient (24 000 years old) horse 
and Przewalski horses (Equus ferus przewalskii) (Table S2). Allele fre-
quencies for early domestic, ancient and Przewalski horses were cal-
culated together and by age of sample.
2.6 | Data analysis
Data analysis was performed at two separate Universities (University 
of California, Davis and University of Nebraska, Lincoln) and re-
viewed by an author at a third University (Oregon State University) 
independent from the author who generated the histopathological 
diagnosis (S.J.V., Neuromuscular Diagnostic Laboratory). A post-hoc 
statistical power analysis was performed to determine if our sample 
sizes were adequate to detect a significant effect, using a medium 
(d = 0.5) effect size. For the WB population, power was calculated 
as 99.6%. For the AR population, post-hoc power was calculated at 
86.6%. Age data that were non-normally distributed by Shapiro-Wilk 
testing were log10 transformed and compared between respective 
control and myopathic groups using an unpaired t-test.
Initially, genotypes at each locus (homozygous reference vs. het-
erozygous, homozygous alternate) were compared using a Fisher's 
exact test between two subgroups of control WB, both of which had 
no evident muscle histopathology. The first subgroup consisted of 
control horses with no potential overlapping clinical signs of PSSM2/
MFM. This included horses with no clinical signs (N = 11) combined 
with control horses with signs of shivers/stringhalt (N = 16; total 
N = 27). Comparison was made to a second subset of the control 
group consisting of WB with clinical signs that overlap those of 
PSSM2/MFM (N = 27) [weakness, lameness, atrophy/fasciculations, 
poor performance, muscle soreness and ER]. Finding no significant 
difference in genotypes between the two subsets of control WB, 
further analyses were performed using the entire control WB group 
that had no evident muscle histopathology.
Control WB and control-AR horses were compared to a com-
bined group of PSSM2 and MFM horses (PSSM2/MFM) by breed 
(Table 2). Control horses were also compared within breed to: 1) 
a PSSM2 group, which included all PSSM2 horses with or without 
MFM and 2) an MFM group, which included all MFM horses with or 
without PSSM2. Genotype and allele frequencies were calculated 
and compared between control and myopathic groups for each of 
the four variants within each breed using a Fisher's exact test; ad-
ditive and dominant models were considered. Out of concern that 
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some WB control horses were younger than the potential age of 
onset for MFM, we also compared PSSM2/MFM-WB genotypes 
(homozygous reference to heterozygous, homozygous variant) at 
each locus between a subset of the control WB horses < 7 years of 
age (N = 20) to a subset ≥ 7 years of age (N = 34) using a Fisher's 
exact test. For an allelic Fisher's exact test, at least five individuals (ie 
10 alleles) are required in both disease and control groups to identify 
a significant association (P < .05) assuming an autosomal dominant 
mode of inheritance.
The term variant was used to define an alternate (nonreference) 
allele at any P locus. The total number of P variant alleles per horse 
across all loci was counted considering P3 as a single locus, as P3a 
and P3b were in complete linkage disequilibrium in these samples. 
Total variant allele count per horse was classified then as none, 
one or >1 (maximum of 6 if the horse was homozygous across P2, 
P3 and P4) for contingency table analyses (Fisher's exact test) to 
compare control vs. myopathic groups within each breed. Counts 
of total loci with a P variant (0 to 3, where 3 = at least one variant 
at P2, P3 and P4) per horse were evaluated similarly. The count of 
loci with one or more P variants for horses classified by P2 and P4 
genotypes (no variants at these loci, variants at only P2, variants 
at only P4 or variants at both P2 and P4) was similarly compared. 
Additionally, to evaluate potential quantitative effects of these 
loci, multiple logistic regression was performed within each breed 
(WB and AR), using PSSM2 and/or MFM as the dependent binary 
variable and including sex (as binary), age (as continuous) and P2, 
P3A and P4 genotypes (as continuous; defined as 0 = homozygous 
reference, 1 = heterozygous and 2 = homozygous alternate allele). 
Lastly, the allele frequencies at each locus were calculated within 
each breed.
The odds ratio, sensitivity, specificity and positive and nega-
tive predictive values of the genetic variants were determined. For 
multiple logistic regression, area under the receiver operator curve 
(ROC AUC) was generated and log-likelihood ratios were used for 
hypothesis testing within each breed. Statistics were performed 
using commercially available software GraphPad Prism (version 8) 
and R (version 3.6.3).26 Data are presented as mean and standard 
deviation; P was set at < .05.
3  | RESULTS
3.1 | Horses
There were 54 control and 68 PSSM2/MFM-WB horses (Table 2) 
with information for horses classified as PSSM2 or MFM separately 
provided in Table S3. Age was not normally distributed and after log 
transformation there was no difference in age between control-WB 
and PSSM2/MFM-WB (P = .2). Thirty control-AR were available for 
comparison to 30 PSSM2/MFM-AR with information for separate 
PSSM2 and MFM groups provided in Table S3. Due to overlap of 
PSSM2 and MFM diagnosis, results for some horses are presented 
in both groups (PSSM2 or MFM). Age was normally distributed and 
there was no significant difference in ages between control-AR and 
PSSM2/MFM-AR (P = .3).
3.2 | Genotype and allele frequencies
All four loci were successfully genotyped in the WB and AR controls 
and MFM/PSSM2 horses; there were no missing data. There were 
no statistically significant differences in genotype (P2 P = .2, P3a/
P3b P =.44, P4 P = .8) when comparing the subgroup of WB control 
horses with no clinical signs/shivers to the subgroup with overlap-
ping clinical features of PSSM2/MFM (Figure S1A). There were no 
statistically significant differences in genotype or allele frequencies 
between all controls and horses classified as PSSM2/MFM, MFM or 
PSSM2 for any of the alternate alleles of P loci analysed by breed 
(Figure 1, Table 3, Table S4). The P2 variant occurred in 15% of con-
trol-WB and 27% of PSSM2/MFM-WB and 20% of control and 33% 
Warmblood Arabian
Control PSSM2/MFM Control PSSM2/MFM











Sex 20 f, 33 mc, 1 s 23 f, 42 mc, 2 s, 1 un 22 f, 8 mc 18 f, 12 mc
GYS1 mutation neg neg nd 13 neg, 17 nd
Muscle biopsied 29 glut, 34 sm 18 glut 50 sm 30 glut 17 glut, 13 sm
Horses with PAS 
aggregates
0 55 0 18
Horses with desmin 
aggregates
0 37 0 30
Abbreviations: AR, Arabian; f, female; Glut, gluteus medius; GYS1, glycogen synthase 1; mc, male 
castrate; MFM, Myofibrillar Myopath; nd, not done; neg, negative; PAS, periodic acid-Schiff's; 
PSSM2, Polysaccharide storage myopathy type 2; s, stallion; Sm, semimembranosus; un, unknown; 
WB, Warmblood.
TA B L E  2   The age (mean and SD range), 
sex, glycogen synthase 1 (GYS1) mutation 
status, muscle biopsied, number of horses 
with PAS-positive aggregates and the 
number with four or more fibres with 
desmin aggregates for Warmblood (WB) 
and Arabian (AR) horse controls and those 
diagnosed with type 2 polysaccharide 
storage myopathy and myofibrillar 
myopathy
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of PSSM2/MFM-AR with an overall frequency (cases and controls) 
of 0.119 in WB and 0.142 in AR. The P3a and P3b variants were in 
complete linkage disequilibrium, occurring in 9% of control-WB and 
12% of PSSM2/MFM-WB and in 3% of AR regardless of phenotype. 
Overall frequencies for the P3 variant in each breed were 0.053 in 
WB and 0.017 in AR. The P4 variant was present in 19% of control-
WB and 24% of PSSM2/MFM-WB as well as 13% of control-AR and 
20% of PSSM2/MFM-AR with breed frequencies of 0.111 in WB 
and 0.092 in AR. There were no statistically significant differences 
in genotype frequencies between control-WB ≥7 years of age and 
PSSM2/MFM-WB for P2, P3a, P3b and P4 variants (P2 P = .07, P3a/
P3b P > .99, P4 P = .4) (Figure S1B). Multiple logistic regression within 
WB and AR did not identify any significant contribution of loci to the 
phenotype (WB – ROC AUC = 0.64 ± 0.05, log-likelihood ratio = 5.86 
(P =.32); AR – ROC AUC = 0.62 ± 0.07, log-likelihood ratio = 3.88 
(P = .57)).
3.3 | Total number of variant alleles and loci
There were no significant differences in the total number of P variants 
or in the number of P loci with at least one variant allele for any locus 
between control and either PSSM2/MFM or MFM or PSSM2 horses 
within breed (Figure 2, Table 4, Table S5). The percentage of horses 
with more than one variant allele across all P loci was 5.6% for control-
WB and 13.2% for PSSM2/MFM-WB and 3.3% for control-AR and 
10% for PSSM2/MFM-AR. The developers of the test have proposed 
that horses with P variants at both P2 and P4 are more likely to have 
severe signs of PSSM2 (http://equis eq.com/blog/p2-p4-linkage). We 
found that the frequency of PSSM2 horses with a variant at both P2 
and P4 was less than 7% in both WB and AR (data not shown) and that 
both P2 and P4 variants were present in control-WB. PSSM2 horses 
did not have significantly different frequencies of P variants at both 
the P2 and P4 loci compared to controls (P = .763).
3.4 | Sensitivity of commercial genetic test variants
The sensitivity for testing ranged from 0.03 (P3 in the WB) to a maxi-
mum of 0.33 (P2 in the WB) (Table 5, Table S6). Odds ratios ranged 
from 0.7 (P4 in the WB) to 2.07 (P2 in the AR); however, all calculated 
confidence intervals included 1 and were therefore not significant.
3.5 | Allele frequencies in public databases
Genotype data were available for the P loci from 107 modern, 85 
early domestic, 1 ancient and 12 Przewalski horses (N = 205 total; 
Table S2). Two samples noted as ‘ancient’ in the SRA were instead 
classified as modern horses due to the reported age of each sam-
ple (between 89 and 267 years old).27 Genotyping rate for the 205 
horses ranged from 0.58 (P3b) to 0.82 (P2). The P2 variant was 
present at a frequency of 0.177 in the modern horses, and 0.176 
in the early domestic horses; its frequency was 0.333 in 18 geno-
typed samples from 3501 to 5500 years ago. The P2 variant was 
also present in five of the 12 Przewalski horses. A third nucleotide 
(C), predicted to result in the substitution of serine with alanine, was 
identified in three Franches-Montagnes (two heterozygous and one 
homozygous; frequency = 0.02). Across all 168 samples in the SRA 
database with a P2 genotype, 32% possessed a P variant (43 het-
erozygotes/11 homozygotes). Within the public database, the P3a 
and P3b variants were not in complete linkage disequilibrium and 
found at frequencies of 0.09 and 0.06, respectively, in the modern 
horses. The P3a variant was identified as early as 5,500 years ago 
and had a frequency of 0.061 in the early domestic horses. The P3b 
variant dated to over 1900 years and was present at a frequency of 
0.047 in early domestic horses. The variant alleles for P2 and P3 were 
found in horses sampled in Central Europe (Estonia), the Middle East 
(Turkey) and Eastern Asia (Mongolia), among other locations across 
Eurasia. The P4 variant was present in 21% of the modern horses 
F I G U R E  1   The percentage of horses homozygous for the reference allele (blue), heterozygous (yellow) or homozygous (red) for P2, P3a/
P3b or P4 in Warmblood and Arabian horse controls and those diagnosed with PSSM2/MFM by muscle histopathology. 54 control-WB, 68 
PSSM2/MFM-WB, 30 control-AR and 30 PSSM2/MFM-AR horses were analysed. There was no significant difference in the frequency of 
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from the database with the allele frequency of 0.135. The P4 vari-
ant was found in the one horse classified as early domestic (dating 
to 467 years before present), accounting for an allele frequency of 
0.008 in the early domestic horses; this horse did not have any alter-
nate alleles at the other P2, P3a and P3b loci.
4  | DISCUSSION
The lack of regulatory requirements for commercial genetic tests for 
horses makes it particularly important to report their diagnostic ac-
curacy in peer-reviewed publications. Our analysis of commercially 
offered genetics tests for PSSM2 or MFM used the gold standard 
of phenotyping via histopathology. We found no association be-
tween any of the test variants, or combinations of test variants, and 
the presence of either PSSM2/MFM considered as one diagnosis, 
or when PSSM2 or MFM were considered separately in AR or WB. 
The sensitivity of the genetic tests, or true positive rate, was low 
at <33% and all confidence intervals for odds ratios included 1, in-
dicating that the variants neither increase nor decrease the odds of 
disease. Healthy control horses were as likely to possess a P2, P3 or 
P4 variant as a horse with PSSM2 or MFM. Thus, we find no support-
ing evidence that the P2, P3 or P4 variants are themselves causative 
or diagnostic of a myopathy in the horse.
We found that P2, P3a and P3ba variants have been present 
in equids long before breed formation. Notably, the identification 
of the P2 variant in Przewalski horses, which are not direct ances-
tors of modern horses, dates the origin of the P2 variant to before 
the divergence of these taxa, estimated at 35 000 to 55 000 years 
ago.28,29 All four P variants identified in horses dated to before 
modern selection practices were established and were additionally 
widely distributed across the breeds studied. Thus, the use of the P 
variant genetic tests in selection decisions, prepurchase examina-
tion or diagnosis of a myopathy is not supported by the findings of 
the current study based on their presence in WB and AR regard-
less of phenotype and their presence in modern, early domestic and 
Przewalski horses.
The importance of assessing the diagnostic value of variants in 
the equine genome is highlighted by the fact that variants in genetic 
sequence, even those which change gene or protein function, are 
common across species. For example, a study of 88 horses from 
diverse breeds found that a single horse, on average, has over 1.8 
million homozygous and over 3.9 million heterozygous SNP vari-
ants compared to the reference genome; of these variants, more 
than 400,000 were predicted to have protein-changing effects.30 
Furthermore, RNA-seq analysis of muscle from eight WB MFM and 
eight control WB horses found 26 missense variants, including P2, 
P3a and P3b, in 16 genes known to cause MFM or MFM-like dis-
eases in humans; none of the variants, however, were associated 
with the MFM phenotype in the eight WB horses.31 The relative 
ease with which genomes can be sequenced using high-through-
put next-generation sequencing and the resultant identification of 
TA B L E  3   The number of horses homozygous for the reference allele, heterozygous or homozygous for each P variant by phenotype and 















Control-WB 54 46 7 1 15% 0.08
PSSM2/MFM-WB 68 50 16 2 27% 0.15 .32 .23
Control-AR 30 24 5 1 20% 0.12
PSSM2/MFM-AR 30 20 10 0 33% 0.17 .82 1.00
P3a/P3b: FLNC- rs1139799323/ FLNC - rs1142918816
Control-WB 54 49 5 0 9% 0.05
PSSM2/MFM-WB 68 60 8 0 12% 0.06 1.00 1.00
Control-AR 30 29 1 0 3% 0.02
PSSM2/MFM-AR 30 29 1 0 3% 0.02 1.00 1.00
P4: MYOZ3 - rs1142544043
Control-WB 54 44 10 0 19% 0.09
PSSM2/MFM-WB 68 52 15 1 24% 0.13 1.00 .82
Control-AR 30 26 4 0 13% 0.07
PSSM2/MFM-AR 30 24 5 1 20% 0.12 .61 1.00
Note: P-values are given for comparisons of the prevalence of the variant in PSSM2/MFM vs. controls using genotypic or dominant models. The 
predicted amino acid substitutions were based upon the variant positions and Ensembl transcript ENSECAT00000076596.1. There were no 
significant differences in the prevalence of the variants or allele frequencies between control and PSSM2/MFM horses of either breed.
Abbreviations: MFM, Myofibrillar Myopathy; PSSM2, Polysaccharide storage myopathy type 2.
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numerous variants in the genome underscore the importance of 
validating associations between a discovered variant and the gold 
standard for diagnosis of the associated disease.
The P2 variant occurs in the gene MYOT and is predicted to 
cause an amino acid substitution of a neutral proline for a neutral 
polar serine in the sarcomeric Z-disc protein myotilin; this substi-
tution is predicted to be tolerated by SIFT analyses. Mutations 
in MYOT are validated causes of MFM in humans; however, the 
validated mutations impact other regions of the myotilin gene than 
P2.32,33,34 In AR, the P2 variant was present in 20% of healthy 
Arabians and absent in 66% of AR with PSSM2/MFM. In WB, 
the P2 variant was present in 15% of healthy WB and absent in 
73% PSSM2/MFM horses. In addition, the P2 variant was found 
in horses of diverse breeds, lesser managed, ‘landrace’ breeds (eg 
Yakutian and Mongolian), early domestic horses and the Przewalski 
horse. Thus, the P2 variant appears to be a common variant long 
F I G U R E  2   The percentage of control 
and PSSM2/MFM Warmblood (WB) and 
Arabian (AR) horses that had more than 
one P2, P3a/P3b or P4 variant alleles. 
There were no significant differences in 
the frequency of horses with none, one 
or more than one variant alleles between 







































TA B L E  4   The total number of control and PSSM2/MFM horses of each breed and counts within each denoting the number of horses 




One Variant  
Allele/Locus
> 1 Variant  
Alleles/Loci




Control-WB 54 33 18/19 3/2 5.6/3.7
PSSM2/MFM-WB 68 33 26/28 9/7 13.2/10.3 0.26/0.23
Control-AR 30 20 9/9 1/1 3.3/3.3
PSSM2/MFM-AR 30 15 12/13 3/2 10.0/6.7 0.35/0.45
Note: P-values are given for comparisons of the number of horses with none, one or >1 P variant allele/loci between control and PSSM2/MFM horses 
by breed.
Abbreviations: AR, Arabian; MFM, Myofibrillar Myopathy; PSSM2, Polysaccharide storage myopathy type 2; WB, Warmblood.
TA B L E  5   The odds ratio (OR), sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the P2, P3 
and P4 variants in PSSM2/MFM horses by breed. P3a and P3b were in complete linkage disequilibrium
Variant
OR Sensitivity Specificity PPV NPV
CI CI CI CI CI
PSSM2/MFM-WB P2 2.07 0.82-5.12 0.27 0.18-0.38 0.85 0.73-0.92 0.69 0.50-0.84 0.48 0.38-0.58
P3 1.31 0.43-3.75 0.12 0.06-0.23 0.91 0.80-0.96 0.62 0.36-0.82 0.45 0.36-0.54
P4 1.35 0.56-3.36 0.24 0.15-0.34 0.82 0.69-0.90 0.62 0.43-0.78 0.46 0.36-0.56
PSSM2/MFM-AR P2 2.00 0.60-7.05 0.33 0.19-0.51 0.80 0.63-0.90 0.63 0.39-0.82 0.55 0.40-0.68
P3 1.00 0.05-19.6 0.03 0.002-0.17 0.97 0.83-0.99 0.50 0.03-0.98 0.50 0.38-0.63
P4 1.62 0.45-5.56 0.20 0.09-0.37 0.87 0.70-0.95 0.60 0.31-0.83 0.52 0.39-0.65
Note: None of the calculated values reached statistical significance (P < .05).
Abbreviations: AR, Arabian; MFM, Myofibrillar Myopathy; NPV, negative predictive value; PPV, positive predictive value; PSSM2, Polysaccharide 
storage myopathy type 2; WB, Warmblood.
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present in equids. Common variants are not necessarily benign; 
however, if a moderately frequent variant itself had a notable im-
pact on phenotype, it would be unlikely to be perpetuated across 
such a time frame. These lines of evidence—its presence across 
evolutionary time, similar frequency in PSSM2/MFM horses and 
controls and lack of a predicted or demonstrated impact on gene 
function—support the conclusion that the P2 variant cannot be 
accurately used to diagnose PSSM2/MFM.
The P3a variant in FLNC is predicted to cause a substitution of 
the acidic amino acid glutamic acid annotated in the reference ge-
nome with the basic amino acid lysine and the P3b variant substitu-
tion of a neutral alanine with threonine. With the exception of P3b 
in one isoform of FLNC, both variants are predicted to be tolerated. 
Mutations in other sites in FLNC, which encode the Z-disc protein 
filamin C, have been shown to cause MFM in humans.14,35 The P3 
variants, in complete linkage disequilibrium in these samples, were 
at low frequency in PSSM2/MFM, PSSM2 and MFM-WB and AR 
horses (< 12% of horses with a variant allele) with no difference in 
frequency compared to control horses. The very low sensitivity of 
the P3 variants for predicting PSSM2/MFM indicates that these P3 
variants cannot accurately be used to diagnose PSSM2 or MFM.
The P4 variant is predicted to cause a deleterious substitution 
of serine with leucine in Z-disc protein myozenin 3 expressed in 
fast-twitch muscle fibres. A very similar protein, myozenin 1, is also 
expressed in fast-twitch myofibres, has a similar function and could 
possibly compensate for a myozenin 3 deficiency.36 Mutations in 
MYOZ3 have not been reported to cause MFM or PSSM2 in any 
species; however, mutations in MYOZ2, solely expressed in cardiac 
muscle, cause a cardiomyopathy characterised by myofibrillar disar-
ray.36 Only 24% of PSSM2/MFM-WB and 20% of PSSM2/MFM-AR 
possessed the P4 variant and the frequency of P4 in PSSM2/MFM 
was not statistically different than control horses. Similar to the re-
sults from the other loci, there is no indication that the P4 variant 
itself is predictive of, or causes, PSSM2/MFM.
It has been argued that a combination of the P variants is required 
for the expression of PSSM2 or MFM. The developers of the test have 
proposed that horses with variants at both P2 and P4 are more likely 
to have severe signs of PSSM2 (http://equis eq.com/blog/p2-p4-link-
age). To investigate the possible role of multiple variants, we compared 
the number of horses with zero, one or more than one variant alleles 
or loci between control and PSSM2/MFM, PSSM2 or MFM, as well as 
the number of horses with at least one alternate allele at both the P2 
and P4 loci. Again, there were no differences between controls and ei-
ther MFM/PSSM2 or PSSM2 or MFM groups in the number of horses 
with multiple variant alleles, multiple variant loci or variant alleles at 
both P2 and P4. Furthermore, logistic regression failed to identify any 
significant contribution of loci to the PSSM2/MFM phenotype. Thus, 
a combination of P variants is not clinically useful to diagnose either 
MFM or PSSM2. It is possible that the alternative alleles at the P loci 
could explain a small proportion of variance in phenotype of MFM/
PSSM2 horses, as would be expected in the case of a complex trait. 
The results of our study, however, do not support their use as diagnos-
tic markers of either PSSM2 or MFM.
No functional evidence has demonstrated that any of the P vari-
ant alleles impact, positively or negatively, the health and fitness of 
the horse. The presence of three nucleotide variants at the P2 locus 
suggests that conservation of this residue is likely not functionally 
important. If any of these variants did confer a disadvantage to 
health and fitness, as would be expected for a horse diagnosed with 
MFM or PSSM2, they would be unlikely to have been perpetuated 
through domestication as well as maintained at relatively high fre-
quency in a diversity of breeds.
One concern in the present study was the definition of control 
horses. For AR horses, control horses had a well-known history with 
no reported episodes of muscle disease and no evidence of muscle 
histopathology. Using this control group, there was no evidence to 
support any of the P variants being associated with a diagnosis of 
PSSM2/MFM by muscle histopathology. For WB horses, there were 
not enough muscle biopsy samples from healthy WB (N = 11) to con-
duct a similar analysis. We elected to define control WB horses as 
those with no evidence of muscle histopathology. Sixteen of these 
horses likely had a neurologic disorder with clinical signs of stringhalt/
shivers.37 Twenty-seven horses had a wide variety of common clinical 
signs in athletic horses ranging from lameness to poor performance 
to sore muscles. To address the concern that some of the control WB 
could have had PSSM2/MFM that was not detected by muscle biopsy, 
we subdivided the WB control group into those with no overlapping 
signs of PSSM2/MFM and those with potential signs of PSSM2/
MFM, such as muscle soreness, rhabdomyolysis, lameness/gait ab-
normalities and poor performance. There were no statistically signif-
icant differences in genotypes for any of the P variants between the 
two control WB subgroups. There was a tendency towards a higher 
frequency of the P2 variant in WB controls with signs that overlap 
PSSM2/MFM; however, in light of the fact that 73% of the PSSM2/
MFM horses diagnosed by histopathology lacked the P2 variant, this 
variant is not a useful diagnostic marker for PSSM2/MFM. The lack of 
any statistical association between any P variant and PSSM2/MFM 
in either the well-defined control and myopathic AR horses or the 
control and myopathic WB horses thus indicates that the P variants 
are not useful as diagnostic tests for PSSM2/MFM.
Because it has not yet been established whether PSSM2 is an ear-
lier manifestation of MFM in WB and AR, we performed our analy-
ses considering them as one disease as well as considering them as 
separate diagnoses. Regardless, we found no significant association 
between any of the P variants and the disease phenotype. MFM is 
considered an adult-onset disease often evident in WB 7 years of 
age or older.9 In our study, ages were similar between control and 
PSSM2/MFM-WB and PSSM2/MFM-AR horses. Nevertheless, we 
performed an additional analysis whereby the WB control horses 
were stratified by age and compared using only WB 7 years of age or 
older to PSSM2/MFM-WB. No significant differences in genotypes 
were found. Although not expected, even if PSSM2/MFM was to de-
velop in some of the control horses used in this study at a later age, 
the low frequency of the variants at these loci in horses that were 
diagnosed with PSSM2 and/or MFM, and thus their low PPVs, again 
demonstrates that these variants are not predictive of PSSM2/MFM.
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It could be argued that PAS or desmin stains are not the most 
accurate way to diagnose PSSM2 or MFM respectively. The pres-
ence of aggregates of PAS or aggregates of desmin-positive mate-
rial, combined with supportive ultrastructural features, however, 
was the means by which these diseases were defined. Protein ag-
gregates of desmin and several other myofibrillar and cytoplasmic 
proteins are a hallmark of MFM in humans that is caused by a wide 
variety of mutations in a wide variety of genes.11,12,13,14,38 Horses 
with desmin aggregates would likely be the most extreme pheno-
type if MFM represents a later stage of PSSM2 in WB and AR and 
therefore, MFM horses would be expected to possess one or more 
P variants if they were predictive of disease. We found, however, 
that <20% of MFM horses possessed one P variant and <22% 
possessed two or more P variants indicating that the presence of 
variants alleles at multiple variant loci is not associated with a diag-
nosis of PSSM2 or MFM. In order to prevent any bias in interpre-
tation, data were carefully evaluated, analysed and interpreted by 
researchers at three Universities (University of Nebraska, Lincoln, 
University of California, Davis and Oregon State University) inde-
pendent of the laboratory performing the histopathological diagno-
ses (Michigan State University). Thus, independent analysis of the 
genotypes of horses diagnosed with PSSM2 or MFM using the cur-
rent gold standards for phenotyping confirmed that there was no 
association between the P2, P3a, P3b and P4 loci and the disease 
phenotype.
In conclusion, the P2, P3 and P4 variants have been perpet-
uated across the timeline of domestication and breed formation 
in horses. Our results indicate that the variants used in commer-
cial genetic tests are not predictive of the presence or absence of 
PSSM2 or MFM in AR and WB diagnosed by the well-established 
criteria of clinical signs and histopathology. Given the frequencies 
identified in these samples, by chance alone 29% of WB and 25% 
of AR will have at least one P variant regardless of their pheno-
type. While a noninvasive means to detect susceptibility to PSSM2 
or MFM at an early age is highly desirable, at present, our study 
findings indicate that a careful history, physical examination, serum 
creatine kinase activity, PSSM1 genetic test and, in the absence of 
PSSM1, muscle histopathology represent more accurate and vali-
dated means to differentiate the many causes of exertional myop-
athies in horses.39,40
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30 Arabians, 68 
Warmbloods with 




P2, P3, P4 variants 
-
Genotyping for 
P2, P3, P4 variants 
- 30% Arabians, 33% Warmbloods
had one of the P variants
- 3% Arabians, 6% Warmbloods
had > 1 P variant
- 40% Arabians, 38% Warmbloods
had one of the P variants
- 10% Arabians, 13% Warm bloods
had > 1 P variant
Test sensitivity for each P variant was < 33% 
P2 and P3 were present in 25 early domestic and modern breeds (public repositories) 
A single or combination of commercial genetic test P variants were not statistically associated with 
a histological diagnosis of PSSM2 and MFM, the means by which these diseases were discovered 
Commercial genetic testing for PSSM2 and myofibrillar myopathy do not correspond to a histopathological diagnosis, 2020;00:1-11. htps://doi.org.10.1111 /
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Figure S1: A. The percentage of horses homozygous for the reference allele (blue), heterozygous (yellow) or homozygous (red) for P2, P3a/P3b, or 
P4 in Warmblood horse. Two subgroups of control WB are presented, both of which had no evident muscle histopathology. The first subgroup 
consisted of control horses with no potential overlapping clinical signs of PSSM2/MFM. This included horses with no clinical signs (N=11) combined 
with control horses with signs of shivers/stringhalt (N=16; total N=27). Comparison was made to a second subset of the control group consisting of 
WB with clinical signs that overlap those of PSSM2/MFM (N=27) [weakness, lameness, atrophy/fasciculations, poor performance, muscle soreness, 
exertional rhabdomyolysis]. There was no significant difference in the frequency of any of the P variants between the two subgroups of control 
horses or between horses with no overlapping signs of PSSM2/MFM and PSSM2/MFM horses. B. Two subgroups of control WB are presented both 
of which had no evident muscle histopathology. The first subgroup was < 7 years of age (N=20) and the second ≥ 7 years of age (N=34). There was 
no significant difference in the frequency of any of the P variants between the two subgroups of control horses or between control horses ≥ 7years of 
age and PSSM2/MFM horses.
Table S1: P variant coordinates, SNP identifiers, and primers utilised for genotyping (EquCab 2) by pyrosequencing. 
SNP Gene Chromo-some Coordinate 













TGGTGA ACATCTCCCCTTGAAG  (T/C) 




TACT TTCACCGTGGACTGC   (G/A) 




TCCACT CGCGTCCATGTGCAG (G/A) 




AACT GATGATGGAAGAGCTGT (C/T) 
Table S2:  Genomes surveyed from the NCBI SRA from which one or more P variant 
genotypes were available.  Genotypes matching the reference allele are denoted by a 
period.  nc indicates the genotype was not called due to failure to meet quality criteria 
(e.g. minimum 5 reads).  Samples are classified as modern, early domestic (400-500 
















































A B C D E F G
P2 P3b P3a P4
RunID/Ref A G G G Classification Breed/Origin
ERR3628174 nc nc . nc Modern Franches-Montagnes
ERR979788 AG nc nc nc Modern Franches-Montagnes
ERR2731061 nc nc nc . Modern Holsteiner
ERR863167 . nc nc nc Modern Icelandic Horse
ERR793393 . nc nc nc Modern Icelandic Horse
ERR3628173 nc nc nc . Modern unknown
ERR1527960 AG nc nc . Modern Franches-Montagnes
ERR1527953 CC nc nc GA Modern Franches-Montagnes
ERR1527954 GG nc nc . Modern Franches-Montagnes
ERR1527957 . nc nc AA Modern Franches-Montagnes
ERR2179540 . nc nc . Modern Franches-Montagnes
ERR979790 AG nc nc . Modern Franches-Montagnes
ERR1545182 . . nc nc Modern German WarmBlood
ERR1545185 . nc nc . Modern German WarmBlood
ERR1545180 . nc nc . Modern German WarmBlood
ERR1527966 . nc nc . Modern Haflinger
ERR2179547 . . nc nc Modern Holsteiner
ERR979800 . nc nc . Modern Quart Horse
ERR3628171 AG . nc nc Modern unknown
ERR1305962 . nc . . Modern American Paint Horse
ERR1527967 . . nc . Modern Dutch Warmblood
ERR979794 . . nc . Modern Franches-Montagnes
ERR979793 GG . . nc Modern Franches-Montagnes
ERR979785 AG . nc . Modern Franches-Montagnes
ERR1527952 . . nc . Modern Franches-Montagnes
ERR979795 AG . nc . Modern Franches-Montagnes
ERR1527961 AG . nc GA Modern Franches-Montagnes
ERR979784 AG GA nc . Modern Franches-Montagnes
ERR1527959 . . nc GA Modern Franches-Montagnes
ERR1527965 AG AA nc AA Modern Franches-Montagnes
ERR1527964 . AA nc GA Modern Franches-Montagnes
ERR466186 . . nc . Modern Franches-Montagnes
ERR2179541 AC . nc GA Modern Franches-Montagnes
ERR1545179 . . nc . Modern German WarmBlood
ERR1545184 . . nc GA Modern German WarmBlood
ERR1545187 . . nc . Modern German WarmBlood
ERR979798 . . . nc Modern Quarter Horse
ERR979797 GG . nc AA Modern Quarter Horse
ERR979802 . . nc . Modern Standardbred
ERR979801 AG . nc . Modern Standardbred
ERR1735862 . nc . . Modern Thoroughbred
ERR979796 . nc . . Modern unknown
ERR1021816 . . nc . Modern Yakutian Horse
ERR1021818 . . nc . Modern Yakutian Horse
















































A B C D E F G
ERR1021824 . GA nc . Modern Yakutian Horse
ERR1021819 . GA nc . Modern Yakutian Horse
ERR1527950 . . . . Modern Akhal-Teke
ERR1527948 . . . . Modern Akhal-Teke
ERR1527949 . . . . Modern Akhal-Teke
ERR1527947 . . . . Modern Akhal-Teke
ERR1305964 . . . . Modern American Paint Horse
ERR1305963 . . . . Modern American Paint Horse
ERR2179544 GG . . . Modern Arabian
ERR2179551 AG . . . Modern Arabian
ERR1527951 . . . . Modern Arabian
ERR1527971 . . . GA Modern Franches-Montagnes
ERR1527955 . . . AA Modern Franches-Montagnes
ERR979792 . . . . Modern Franches-Montagnes
ERR979789 AG . . . Modern Franches-Montagnes
ERR1527962 AG . GA . Modern Franches-Montagnes
ERR979787 . . . GA Modern Franches-Montagnes
ERR979791 AC . . . Modern Franches-Montagnes
ERR979786 AG GA GA GA Modern Franches-Montagnes
ERR1527963 AG GA GA . Modern Franches-Montagnes
ERR1527956 AG . . . Modern Franches-Montagnes
ERR1527958 AG . . GA Modern Franches-Montagnes
ERR2179545 . . . . Modern German Riding Pony
ERR2179542 . . . . Modern German Riding Pony
ERR1545183 AG . . . Modern German Warmblood
ERR1545178 . . . GA Modern German Warmblood
ERR1545189 . . . . Modern German Warmblood
ERR1545190 . . . . Modern German Warmblood
ERR1545186 . . . . Modern German Warmblood
ERR1545181 . . . . Modern German Warmblood
ERR1545188 . . . . Modern German Warmblood
ERR2179553 . . . . Modern Haflinger
ERR2179554 . . . . Modern Haflinger
ERR2179555 AG . . . Modern Haflinger
ERR2179549 AG . . . Modern Hannoveraner
ERR2731057 . . . . Modern Icelandic Horse
ERR982704 AG . . . Modern Mongolian
ERR2179546 AG . . AA Modern Morgan Horse
ERR2179552 . . . . Modern Noriker
ERR2179548 . . . . Modern Oldenburg Horse
ERR982707 AG . . . Modern Polish Warmblood
ERR979799 AG . . . Modern Quarter Horse
ERR1527969 . . . . Modern Quarter Horse
ERR1527970 . . . . Modern Quarter Horse
ERR1527968 . . . . Modern Quarter Horse
ERR868004 . . . . Modern Shetland Pony
































A B C D E F G
ERR979803 AG . . . Modern Standardbred
ERR1512897 . . . GA Modern Standardbred
ERR2179556 . . . . Modern Swiss Warmblood
ERR1527972 . . . . Modern Swiss Warmblood
ERR2203766 . GA GA GA Modern Trakehner








ERR2179543 . . . AA Modern Welsh Pony
ERR2179550 . . . . Modern Welsh Pony
ERR1021822 . . . . Modern Yakutian Horse
ERR1021817 . . . . Modern Yakutian Horse
ERR1021821 GG . . . Modern Yakutian Horse
ERR1021820 . GA GA . Modern Yakutian Horse
ERR3225567 nc . nc nc Modern Thoroughbred
ERR3225630 nc GA . nc Modern UK
ERR3225467 . . . GA
Early Domestic 
(400-1500 years) France
ERR3225602 . nc . .
Early Domestic 
(400-1500 years) Mongolia
ERR3225600 . . . .
Early Domestic 
(400-1500 years) Mongolia
ERR3225559 nc . nc nc
Early Domestic 
(400-1500 years) Lithuania
ERR3225580 AG nc nc nc
Early Domestic 
(400-1500 years) Estonia
ERR3225562 nc . nc .
Early Domestic 
(400-1500 years) Lithuania
ERR3225639 . . . .
Early Domestic 
(400-1500 years) Turkey
ERR3225570 nc . . .
Early Domestic 
(400-1500 years) Croatia
ERR3225558 nc . . nc
Early Domestic 
(400-1500 years) Lithuania
ERR2112789 . . nc .
Early Domestic 
(400-1500 years) Kazakhstan
ERR3225483 . nc . nc
Early Domestic 
(400-1500 years) Kyrgyzstan
ERR3225482 . GA GA nc
Early Domestic 
(400-1500 years) Kyrgyzstan
ERR3225635 nc . . nc
Early Domestic 
(400-1500 years) Turkey
ERR3225544 . . . .
Early Domestic 
(400-1500 years) Mongolia
ERR3225655 . . . .
Early Domestic 
(400-1500 years) Turkey























A B C D E F G
ERR3225637 . . . .
Early Domestic 
(400-1500 years) Turkey
ERR3225636 . . nc nc
Early Domestic 
(400-1500 years) Turkey
ERR3225643 . nc nc nc
Early Domestic 
(400-1500 years) Turkey
ERR3225658 nc nc nc .
Early Domestic 
(400-1500 years) Turkey
ERR3225646 nc nc . nc
Early Domestic 
(400-1500 years) Turkey
ERR3225648 nc nc nc .
Early Domestic 
(400-1500 years) Turkey
ERR3225654 . . . .
Early Domestic 
(400-1500 years) Turkey
ERR3225657 AG GA AA .
Early Domestic 
(400-1500 years) Turkey
ERR3225593 . . . .
Early Domestic 
(1501-2500 years) Iran
ERR3225647 . GA nc .
Early Domestic 
(1501-2500 years) Turkey
ERR3225549 AG nc nc nc
Early Domestic 
(1501-2500 years) Iran
ERR2112797 . . nc .
Early Domestic 
(1501-2500 years) Turkey
ERR3225481 nc nc nc .
Early Domestic 
(1501-2500 years) France
ERR3225640 . GA nc nc
Early Domestic 
(1501-2500 years) Turkey
ERR3225552 nc . nc nc
Early Domestic 
(1501-2500 years) France
ERR3225527 . nc nc nc
Early Domestic 
(1501-2500 years) France
ERR3225530 nc . nc nc
Early Domestic 
(1501-2500 years) Germany
ERR3225515 nc nc nc .
Early Domestic 
(1501-2500 years) France
ERR3225504 nc nc GA .
Early Domestic 
(1501-2500 years) France




















A B C D E F G
ERR2112790 nc . nc nc
Early Domestic 
(1501-2500 years) Germany
ERR2112788 AG . . nc
Early Domestic 
(1501-2500 years) Mongolia
ERR3225532 nc . . .
Early Domestic 
(1501-2500 years) Mongolia
ERR3225534 AG . nc .
Early Domestic 
(1501-2500 years) Mongolia
ERR3225531 . nc . .
Early Domestic 
(1501-2500 years) Mongolia
ERR3225533 . nc nc nc
Early Domestic 
(1501-2500 years) Mongolia
ERR3225535 nc . . nc
Early Domestic 
(1501-2500 years) Mongolia
ERR3225586 nc . nc nc
Early Domestic 
(1501-2500 years) France
ERR3225453 nc nc nc .
Early Domestic 
(1501-2500 years) France
ERR3225451 . nc nc nc
Early Domestic 
(1501-2500 years) France
ERR2112715 . . nc nc
Early Domestic 
(1501-2500 years) France
ERR3225459 nc . . nc
Early Domestic 
(1501-2500 years) Russia
ERR3225523 nc nc . nc
Early Domestic 
(2501-3500 years) Spain
ERR3225579 AG GA nc .
Early Domestic 
(2501-3500 years) Estonia
ERR2112796 . nc . .
Early Domestic 
(2501-3500 years) Mongolia
ERR3225621 AG . . .
Early Domestic 
(2501-3500 years) Mongolia




















A B C D E F G
ERR3225617 nc . nc nc
Early Domestic 
(2501-3500 years) Mongolia
ERR3225622 nc nc . nc
Early Domestic 
(2501-3500 years) Mongolia
ERR3225620 . nc nc .
Early Domestic 
(2501-3500 years) Mongolia
ERR3225615 nc . nc .
Early Domestic 
(2501-3500 years) Mongolia
ERR3225623 . . . .
Early Domestic 
(2501-3500 years) Mongolia
ERR3225619 nc . . .
Early Domestic 
(2501-3500 years) Mongolia
ERR2112795 . . . .
Early Domestic 
(2501-3500 years) Mongolia
ERR3225618 . . . .
Early Domestic 
(2501-3500 years) Mongolia
ERR2112763 nc nc nc .
Early Domestic 
(2501-3500 years) Russia
ERR3225465 . nc . nc
Early Domestic 
(2501-3500 years) Russia
ERR3225541 . nc nc nc
Early Domestic 
(3501-5500 years) Kazakhstan
ERR3225489 . nc nc nc
Early Domestic 
(3501-5500 years) Spain
ERR3225490 . nc nc .
Early Domestic 
(3501-5500 years) Spain
ERR2112765 AG . . .
Early Domestic 
(3501-5500 years) Kazakhstan
ERR2112768 . nc . nc
Early Domestic 
(3501-5500 years) Kazakhstan
ERR2112767 AG . . .
Early Domestic 
(3501-5500 years) Kazakhstan

























A B C D E F G
ERR2112764 nc . . .
Early Domestic 
(3501-5500 years) Kazakhstan
ERR3225666 nc nc nc .
Early Domestic 
(3501-5500 years) Kazakhstan
ERR2112780 . nc nc nc
Early Domestic 
(3501-5500 years) Kazakhstan
ERR2112716 nc nc nc .
Early Domestic 
(3501-5500 years) Kazakhstan
ERR2112719 AG nc nc .
Early Domestic 
(3501-5500 years) Kazakhstan
ERR3225669 AG nc nc .
Early Domestic 
(3501-5500 years) Kazakhstan
ERR2112774 . . . nc
Early Domestic 
(3501-5500 years) Kazakhstan
ERR2112772 AG . . .
Early Domestic 
(3501-5500 years) Kazakhstan
ERR2112776 . nc nc nc
Early Domestic 
(3501-5500 years) Kazakhstan
ERR2112778 nc GA nc nc
Early Domestic 
(3501-5500 years) Kazakhstan
ERR2112777 . nc nc nc
Early Domestic 
(3501-5500 years) Kazakhstan
ERR2112771 . nc . nc
Early Domestic 
(3501-5500 years) Kazakhstan
ERR2112773 AG . . .
Early Domestic 
(3501-5500 years) Kazakhstan
ERR2112769 GG . . .
Early Domestic 
(3501-5500 years) Kazakhstan
ERR2112770 GG . . .
Early Domestic 
(3501-5500 years) Kazakhstan
ERR3225563 . . . .
Ancient (~24000 
years) Russia
ERR982705 . . nc . Przewalski
ERR982714 AG . nc . Przewalski
ERR982717 AG . . . Przewalski
ERR982706 AG . . . Przewalski
ERR982708 GG . . . Przewalski







A B C D E F G
ERR982718 . . . . Przewalski
ERR982709 . . . . Przewalski
ERR982712 . . . . Przewalski
ERR982715 GG . . . Przewalski
ERR982721 nc nc . nc Przewalski




Table S3: The age, sex, glycogen synthase 1 (GYS1) mutation status, number of horses with PAS positive aggregates and number of horses with 4 or more 
fibres with desmin aggregates for control, type 2 polysaccharide storage myopathy (PSSM2) and myofibrillar myopathy (MFM) presented by breed 
(Warmblood (WB) and Arabian (AR)).  
f = female; mc = male castrate; s = stallion; un = unknown 
neg = negative; nd = not done  
GYS1 = glycogen synthase 1  
PAS= periodic acid Schiff's 
PSSM2 = Polysaccharide storage myopathy type 2 
MFM = Myofibrillar Myopathy  
Warmblood Arabian 
Control PSSM2 MFM Control PSSM2 MFM 
N 54 55 37 30 18 30 
Age (y) 8.6 ± 4.3 9.7 ± 4.7 10.1 ± 4.8 12.4 ± 5.9 13.2 ± 3.8 13.9 ± 5.7 
Sex 20 f, 33 mc, 1 s 19 f, 34 mc, 2 s 15 f, 19 mc, 2 s, 1 un 22 f, 8 mc 10 f, 8 mc 18 f, 12 mc 
GYS1 mutation neg neg neg nd 9 neg, 9 nd 13 neg, 17 nd 
PAS   aggregates 0 55 24 0 18 18 
Desmin aggregates 0 24 37 0 18 30 
Table S4: The number of horses of each phenotype, number of horses homozygous for the reference allele, heterozygous or homozygous for each P variant, 
the percentage of horses possessing the P variant and the variant allele frequencies in control and PSSM2 and MFM Warmbloods (WB) and Arabians (AR) 
phenotyped on the basis of muscle histopathology.  P-values are given for comparisons of the prevalence of the variant in PSSM2 or MFM versus controls 
using genotypic or dominant models. The predicted amino acid substitutions were based upon the variant positions and Ensembl transcript 
ENSECAT00000076596.1. There were no significant differences in the prevalence of the variants or allele frequencies between control and PSSM2 or MFM 












P2  MYOT- rs1138656462 
Control-WB 54 46 7 1 15% 0.08 
PSSM2-WB 55 41 12 2 25% 0.15 0.23 0.44 
MFM-WB 37 27 9 1 27% 0.15 0.19 0.82 
Control-AR 30 24 5 1 20% 0.12 
PSSM2-AR 18 14 4 0 22% 0.11 1.00 0.34 
MFM-AR 30 20 10 0 33% 0.17 0.38 0.23 
P3a/P3b  FLNC- rs1139799323 / FLNC - rs1142918816 
Control-WB 54 49 5 0 9% 0.05 
PSSM2-WB 55 49 6 0 11% 0.05 0.74 1.00 
MFM-WB 37 32 5 0 14% 0.07 0.74 1.00 
Control-AR 30 29 1 0 3% 0.02 
PSSM2-AR 18 17 1 0 6% 0.03 1.00 0.73 
MFM-AR 30 29 1 0 3% 0.02 1.00 1.00 
P4  MYOZ3 - rs1142544043 
Control-WB 54 44 10 0 19% 0.09 
PSSM2-WB 55 43 11 1 22% 0.12 0.81 0.82 
MFM-WB 37 27 10 0 27% 0.14 0.44 1.00 
Control-AR 30 26 4 0 13% 0.07     
PSSM2-AR 18 15 2 1 17% 0.11 1.00 0.44 
MFM-AR 30 24 5 1 20% 0.12 0.73 0.73 
 
Table S5: A. The number of horses with no P variant alleles, one P variant allele, or > 1 P variant 
allele, and the percentage of horses that possessed > 1 P variant allele across all three loci.  P-values 
are given for comparisons of the number of horses with none, one, or > 1 P variant allele between 
control and PSSM2 or MFM horses by breed. B. The number of horses with no P variant loci, one P 
variant locus, or > 1 P variant locus, and the percentage of horses that possessed > 1 P variant locus. 
P-values represent the comparisons of the number of horses with none, one, or > 1 variant loci











Control-WB 54 33 18 3 
PSSM2-WB 55 29 18 8 0.33 
MFM -WB 37 15 18 4 0.15 
Control-AR 30 20 9 1 
PSSM2-AR 18 10 7 1 0.68 











Control-WB 54 33 19 2 
PSSM2-WB 55 29 20 6 0.36 
MFM -WB 37 15 19 3 0.13 
Control-AR 30 20 9 1 
PSSM2-AR 18 10 8 0 0.61 
MFM -AR 30 15 13 2 0.41 
Table S6: The odds ratio (OR), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) with confidence intervals (CI) for the 
P2, P3 and P4 variants in PSSM2 or MFM horses by breed. P3a and P3b are reported together as they were in linkage disequilibrium. None of the calculated 
values reached statistical significance (p<0.05). 
Variant OR Sensitivity Specificity PPV NPV 
CI CI CI CI CI 
PSSM2-WB 
P2 1.96 0.78 - 5.18 0.26 0.16 - 0.38 0.85 0.73 - 0.92 0.64 0.43 - 0.80 0.53 0.43 - 0.63 
P3a/P3b 1.20 0.32 - 3.8 0.11 0.05 - 0.23 0.91 0.80 - 0.97 0.55 0.28 - 0.80 0.50 0.40 - 0.61 
P4 1.23 0.49 - 3.31 0.22 0.13 - 0.34 0.81 0.69 - 0.90 0.55 0.35 - 0.73 0.51 0.40 - 0.61 
MFM-WB 
P2 2.13 0.79 - 6.36 0.27 0.15 - 0.43 0.85 0.73 - 0.92 0.56 0.34 - 0.75 0.63 0.52 - 0.73 
P3a/P3b 1.53 0.45 - 5.25 0.14 0.06 - 0.29 0.91 0.80 - 0.97 0.50 0.24 - 0.77 0.61 0.50 - 0.71 
P4 1.63 0.64 - 4.15 0.27 0.15 - 0.43 0.82 0.69 - 0.90 0.50 0.30 - 0.70 0.62 0.50 - 0.72 
PSSM2-AR 
P2 1.14 0.21 - 4.16 0.22 0.09 - 0.45 0.80 0.63 - 0.91 0.40 0.17 - 0.69 0.63 0.47 - 0.77 
P3a/P3b 1.71 0.08 - 33.38 0.06 0.001 - 0.13 0.97 0.83 - 1.10 0.50 0.03 - 0.98 0.63 0.49 - 0.76 
P4 1.30 0.29 - 5.36 0.17 0.06 - 0.39 0.87 0.70 - 0.95 0.43 0.16 - 0.75 0.63 0.48 - 0.76 
MFM-AR 
P2 2.00 0.60 - 7.05 0.33 0.19 - 0.51 0.80 0.63 - 0.91 0.62 0.39 - 0.82 0.55 0.40 - 0.68 
P3a/P3b 2.00 0.05 - 19.60 0.03 0.002 - 0.18 1.97 0.83 - 1.01 1.50 0.03 - 0.98 1.50 0.38 - 0.64 
P4 1.63 0.45 - 5.56 0.20 0.095 - 0.37 0.87 0.70 - 0.95 0.60 0.31 - 0.83 0.52 0.39 - 0.65 
